{"groups":[{"description":"Control therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus placebo (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"FG000","title":"Arm I (Placebo, Paclitaxel, Carboplatin)"},{"description":"Bevacizumab-initiation therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"FG001","title":"Arm II (Placebo, Paclitaxel, Carboplatin, Bevacizumab)"},{"description":"Bevacizumab-throughout therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received bevacizumab, 15 mg/kg every 3 weeks.","id":"FG002","title":"Arm III (Paclitaxel, Carboplatin, Bevacizumab)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"309"},{"groupId":"FG001","numSubjects":"274"},{"groupId":"FG002","numSubjects":"195"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"52"},{"groupId":"FG002","numSubjects":"47"}],"type":"Patient Refusal"},{"reasons":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"88"},{"groupId":"FG002","numSubjects":"108"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"11"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"4"}],"type":"Concomitant disease"},{"reasons":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"88"},{"groupId":"FG002","numSubjects":"27"}],"type":"Other Reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"}],"type":"Did not receive study treatment"}],"milestones":[{"achievements":[{"comment":"Total enrolled and included in efficacy analysis","groupId":"FG000","numSubjects":"625"},{"comment":"Total enrolled and included in efficacy analysis","groupId":"FG001","numSubjects":"625"},{"comment":"Total enrolled and included in efficacy analysis","groupId":"FG002","numSubjects":"623"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"107"},{"groupId":"FG001","numSubjects":"112"},{"groupId":"FG002","numSubjects":"227"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"518"},{"groupId":"FG001","numSubjects":"513"},{"groupId":"FG002","numSubjects":"396"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Between October 2005 and June 2009, 1873 women were enrolled from 336 institutions in the United States, Canada, South Korea, and Japan."}